Since the first demonstration that naked plasmid DNA The inferred amino acid sequence, based on the nucleotide sequence of pspA from S. pneumoniae R×1, 9 predicts could elicit protective immune responses, 1 there has been considerable interest in the emerging technology of DNA that the N-terminal half of PspA is a charged ␣-helical domain. It is in this portion of the protein, which is immunization. DNA immunization has been demonstrated to be an effective means of eliciting immunity in thought to be exposed to the environment, that the majority of protection-eliciting epitopes reside. 10 This is a number of model systems. 2 As a model for DNA immunization against bacteria, we have chosen the gene followed by a proline-rich domain, then ten 20-aminoacid repeats, and a slightly hydrophobic sequence of 17-that encodes pneumococcal surface protein A (PspA) of Streptococcus pneumoniae which is a protein that has been amino-acids. 9 The attachment of PspA to the surface of the pneumococcus is via a choline binding site whose forshown to elicit protection against pneumococcal challenge in mice. 3 mation is dependent on the presence of the repeat domain of PspA.
11
Our laboratory has been involved in biological and molecular studies of PspA. We have been studying the We now report that intramuscular injection of BALB/c mice with a plasmid expressing PspA elicits protective role of PspA in pneumococcal virulence and evaluating its potential as a vaccine candidate. PspA is expressed on immunity against experimental pneumococcal infection. the surface of all pneumococci 4 and is able to elicit protective immunity in mice. 3, 5 PspA is required for full viruCloning and expression of PspA lence and slows the clearance of pneumococci from the blood of infected mice. 5 The apparent molecular weight Using oligonucleotide primers LSM17 (5′GCGGATCCGT AGCCAGTCAGTCTAAAGCTG3′) and LSM18 (5′G of PspA is variable (60-130 kDa). 4, 6, 7 Despite the antigenic variability of PspA, we have observed extensive cross-CGGAATTCCCATTCACCATTGGCATTGACTTTAT3′) which were derived from the sequence of pspA from S. reactions between antibodies against variant PspAs. Immunization with a single PspA can elicit protective pneumoniae R×1, we carried out the polymerase chain reaction (PCR) on R×1 genomic DNA as previously immunity against pneumococcal strains of different capsular serotypes. 3, 8 described.
10 The amplified fragment of pspA, which should express full-length PspA, was cloned into pGT41. The plasmid pGT41 contains a CMV promoter and a portion of the gene that encodes RSVG such that when an membrane where it might be exposed to the host immune system. The plasmid derived from pGT41 containing the PspA pKSD2601 was used to immunize BALB/c mice. An additional group of mice received pGT41, the vector 2 × 10 6 colony-forming units (c.f.u.) of capsular serotype alone with no pneumococcal DNA inserted, as a control.
3 S. pneumoniae A66 (about 20 × LD 50 for BALB/c mice). Experiments were done twice using groups of five mice.
At 24 h after challenge, the mice were bled, as previously Mice received lingual injections of 50 g of purified plasdescribed. 13 The number of c.f.u. of pneumococci per ml mid at weekly intervals for 5 weeks. At the end of the of blood was determined by plating 10-fold serial sixth week, mice were bled and the PspA-specific serum dilutions of the samples on blood agar. Although there antibody level of each mouse was determined (Table 1) .
was some overlap in the numbers of c.f.u. observed with The antibody concentration was determined by an ELISA the immunized and control mice, the immunized mice on in which the microtitration plates were coated with puraverage had about one and a half to more than two logs ified PspA versus control plates coated with sham purless pneumococci per ml of blood than the control mice ified PspA from the PspA − mutant pneumococcal strain (Table 2) . When the mean log c.f.u./ml for the two WG44.1.
5 An anti-PspA MAb of known concentration groups were compared (immunized = 2.97 ± 0.25 versus was used as a standard for estimation of antibody concontrol = 4.95 ± 0.59), this difference was significant at centration in the mice. P = 0.0015 based on a Wilcoxon two sample rank test. We also assayed the saliva and feces for the presence The effects of immunization could also be seen in proof anti-PspA antibodies from some of the immunized and tection from death ( Figure 2 ). Forty per cent of the mice control mice. No anti-PspA antibodies were detected that were immunized with pKSD2601 survived, whereas (data not shown) indicating a lack of mucosal immune none of the control mice survived. Moreover, the median response.
time of death of the mice immunized with pKSD2601 was The mice were then challenged intravenously with about 100 h as compared with about 75 h for the nonimmune mice. The difference in survival time of the two groups was significant at P = 0.007. These studies demonstrate that intramuscular immuni- DNA immunization has been shown to be effective against a number of pathogens.
2 To our knowledge this is the first report of protection elicited by DNA immunization against a gram-positive encapsulated bacterial pathogen. The pneumococcus is an important mucosal pathogen against which an effective vaccine is needed. DNA immunization offers the possibility of having an inexpensive multicomponent vaccine. Such a vaccine could be especially important in developing countries where money for vaccination is limited and the incidence of pneumococcal infection is especially high.
